“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

€3.03

SKU: product-article-16332 Category: General

Description
Reviews (0)

Description

PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

Reviews

There are no reviews yet.

Be the first to review “Article: PP71 Impact of Tofacitinib on xenogeneic graft versus host disease”

You must be logged in to post a review.

Top

Article: PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

Description

Reviews

Related products

Article: Highlights in urologic cancer

Article: Highlights in respiratory oncology

Article: Highlights in gynaecological cancers

Article: Highlights in digestive oncology